300158.SZ
振东制药
SZSE · Healthcare · C 制造业 · CN
CNY 5.10
−2.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.7B | 2.8B | 3.0B | 3.6B | 3.7B |
| Cost of Revenue | 1.3B | 1.4B | 1.6B | 1.8B | 1.9B |
| Gross Profit | 1.4B | 1.4B | 1.4B | 1.8B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 176.9M | 179.9M | 351.5M | 191.0M | 178.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 334.0M | 327.6M | 301.2M | 285.9M | 290.9M |
| Selling & Marketing Expense | 1.2B | 1.2B | 1.1B | 1.5B | 1.5B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.7B | 1.7B | 1.8B | 2.0B | 2.0B |
| Cost and Expenses | 3.0B | 3.1B | 3.4B | 3.8B | 3.9B |
| Operating Income (EBIT) | (273.5M) | (264.9M) | (714.7M) | (30.0M) | (5.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (281.3M) | (277.6M) | (1.3B) | (37.7M) | (5.3M) |
| Income Tax Expense | 24.0M | 25.5M | 17.9M | 10.2M | 51.7M |
| Bottom Line | |||||
| Net Income | (303.3M) | (301.1M) | (1.3B) | (44.0M) | (51.3M) |
| Earnings from Cont. Ops | (305.3M) | (303.1M) | (1.3B) | (47.9M) | (57.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (303.3M) | (301.1M) | (1.3B) | (44.0M) | (51.3M) |
| Per Share | |||||
| Basic EPS | (CN¥0.30) | (CN¥0.30) | (CN¥1.30) | (CN¥0.04) | (CN¥0.05) |
| Diluted EPS | (CN¥0.30) | (CN¥0.30) | (CN¥1.30) | (CN¥0.04) | (CN¥0.05) |
| Revenue Per Share | CN¥2.82 | CN¥2.77 | CN¥2.90 | CN¥3.53 | CN¥3.63 |
| Shares | |||||
| Basic Shares Outstanding | 950.8M | 1.0B | 1.0B | 1.0B | 1.0B |
| Diluted Shares Outstanding | 950.8M | 1.0B | 1.0B | 1.0B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | (138.5M) | (595.7M) | 100.5M | 141.1M |
| D&A | — | 126.4M | 119.0M | 130.5M | 147.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026